Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <i>BRCA</i> -Mutant Ovarian Cancer ModelsHyoung Kim, Fiona Simpkins|Clinical Cancer Research|2016Cited by 292
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Fiona Simpkins|JCI Insight|2017Cited by 71
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancerHaineng Xu, Fiona Simpkins|iScience|2024Cited by 11
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRFiona Simpkins, Gary S. Marshall|Research Square|2024Cited by 3
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancerFiona Simpkins, Ronny Drapkin|Research Square|2023Cited by 2